Merck & Company Raises Revenue Guidance Amid Strong Product Performances

Merck & Company (6MK) reported its Q2 2026 earnings results, which showed a positive commercial and scientific story. The company's core revenue growth was 5% in Q2, driven by strong product performances from KEYTRUDA, WELIREG, and WINREVAIR. These products saw significant sales growth, with KEYTRUDA family sales reaching $8.4 billion, up 4% year-over-year.

Merck also reported positive Phase III readouts for several of its pipeline candidates, including sac-TMT, tulisokibart induction, and islatravir combos. The company's vaccines and pneumococcal business saw momentum with GARDASIL sales reaching $1.2 billion and CAPVAXIVE sales growing 40%.

Despite these positives, Merck faced material one-time charges from the Terns acquisition, which resulted in a GAAP loss and drove volatility in its tax rate, margin, and expenses. Management emphasized pipeline derisking, continued launches, and long-term opportunity while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.